{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:07:53Z","timestamp":1782785273424,"version":"3.54.5"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T00:00:00Z","timestamp":1672617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T00:00:00Z","timestamp":1672617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Health and Labor Sciences Research Grant on Intractable Diseases (Neuroimmunological Diseases) from the Ministry of Health, Labor and Welfare of Japan","award":["20FC1030"],"award-info":[{"award-number":["20FC1030"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s13760-022-02162-1","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T10:25:17Z","timestamp":1672655117000},"page":"979-982","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Minimal symptom expression achievement over time in generalized myasthenia gravis"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9252-1863","authenticated-orcid":false,"given":"Akiyuki","family":"Uzawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manato","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Akamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,2]]},"reference":[{"issue":"10","key":"2162_CR1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023\u20131036","journal-title":"Lancet Neurol"},{"issue":"4","key":"2162_CR2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M et al (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87(4):419\u2013425","journal-title":"Neurology"},{"issue":"6","key":"2162_CR3","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/mus.25397","volume":"55","author":"K Utsugisawa","year":"2017","unstructured":"Utsugisawa K, Nagane Y, Akaishi T et al (2017) Early fast-acting treatment strategy against generalized myasthenia gravis. Muscle Nerve 55(6):794\u2013801","journal-title":"Muscle Nerve"},{"issue":"1","key":"2162_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","volume":"70","author":"A Jaretzki III","year":"2000","unstructured":"Jaretzki A III, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America. Ann Thorac Surg 70(1):327\u2013334","journal-title":"Ann Thorac Surg"},{"issue":"7","key":"2162_CR5","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia gravis activities of daily living profile. Neurology 52(7):1487\u20131489","journal-title":"Neurology"},{"issue":"7","key":"2162_CR6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20(7):526\u2013536","journal-title":"Lancet Neurol"},{"issue":"7","key":"2162_CR7","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","volume":"267","author":"J Vissing","year":"2020","unstructured":"Vissing J, Jacob S, Fujita KP, O\u2019Brien F, Howard JF, REGAIN study group (2020) \u2018Minimal symptom expression\u2019 in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol 267(7):1991\u20132001","journal-title":"J Neurol"},{"issue":"10","key":"2162_CR8","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1007\/s00415-021-10520-x","volume":"268","author":"Y Ozawa","year":"2021","unstructured":"Ozawa Y, Uzawa A, Yasuda M et al (2021) Long-term outcomes and prognostic factors in generalized myasthenia gravis. J Neurol 268(10):3781\u20133788","journal-title":"J Neurol"},{"issue":"1","key":"2162_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/cen3.12180","volume":"6","author":"H Murai","year":"2015","unstructured":"Murai H (2015) Japanese clinical guidelines for myasthenia gravis: putting into practice. Clin Exp Neuroimmunol 6(1):21\u201331","journal-title":"Clin Exp Neuroimmunol"},{"issue":"2","key":"2162_CR10","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/mus.23398","volume":"46","author":"M Masuda","year":"2012","unstructured":"Masuda M, Utsugisawa K, Suzuki S et al (2012) The MG-QOL15 Japanese version: validation and associations with clinical factors. Muscle Nerve 46(2):166\u2013173","journal-title":"Muscle Nerve"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-022-02162-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-022-02162-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-022-02162-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T11:10:14Z","timestamp":1685704214000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-022-02162-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,2]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["2162"],"URL":"https:\/\/doi.org\/10.1007\/s13760-022-02162-1","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,2]]},"assertion":[{"value":"9 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AU has received honoraria from Alexion Pharmaceuticals and Argenx. Other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Patients were enrolled via an opt-out methodology. This study protocol and the opt-out method were approved by the ethics committee of Chiba University (IRB No. 2266). We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}